Kang et al. [65] analyzed genetic predictors of ketamine response in patients with TRD, reporting novel associations in genes regulating synaptic vesicle trafficking (SYNGR1, VAMP2) and immune regulation (IL6R, TNFAIP3). This evidence concerns the gene SYNGR1 and treatment resistant depression.